c-Raf 在 KRas 突变型癌症中的作用：一个移动的靶点。
c-Raf in KRas Mutant Cancers: A Moving Target.
机构信息
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
出版信息
Cancer Cell. 2018 Feb 12;33(2):158-159. doi: 10.1016/j.ccell.2018.01.017.
Abstract
Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRas/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.
摘要
针对 KRas 癌症的治疗仍然是一个主要的临床需求。在本期《癌细胞》中，Sanclemente 及其同事在 Mariano Barbacid 小组的研究中验证了 c-Raf 是这些癌症的主要靶点。c-Raf 缺失导致晚期 KRas/Trp53 肿瘤的消退，没有明显的全身毒性，也不影响 MAPK 信号通路。
Zotero 插件